Abstract 3554
Background
The phase 3 SPARTAN study evaluated the efficacy and safety of APA vs placebo (PBO) in men with high-risk nmCRPC. Because dose reductions/interruptions for the management of AEs that occur during treatment can affect drug efficacy, this analysis sought to understand the relationship of APA pharmacokinetic exposure and the primary end point of SPARTAN, MFS.
Methods
1207 pts were randomized in a 2:1 ratio to APA 240 mg/d or PBO. APA levels, and that of its active metabolite N-desmethyl APA (NAPA), were measured by a validated LC/MS/MS assay. APA and NAPA exposures were quantified as the area under the concentration–time curve at steady state (AUC24) at the average daily dose received, up to the MFS event. Exposure levels were evaluated as quartiles or continuous variables. Univariate and multivariate Cox regression models evaluated the relationship between APA/NAPA exposure and MFS and were adjusted by pre-specified stratification factors (prostate-specific antigen doubling time, bone-sparing agent use, locoregional disease status) and other potential prognostic factors (age, ECOG PS).
Results
1206 pts were included in the analysis. AEs led to dose reduction/interruption in 33% vs 19% of APA and PBO pts, respectively, with average daily dose of 225 mg (APA) vs 229 mg (PBO) in pts with dose reduction/interruption. Mean (coefficient of variation [CV]%) PK exposure levels measured as AUC24 for APA and NAPA, respectively, were 117 (24 CV%) μg·h/mL and 155 (17 CV%) μg·h/mL for APA-treated pts without dose reductions/interruptions, and 112 (24 CV%) μg·h/mL and 148 (18 CV%) μg·h/mL for those with dose reductions/interruptions. MFS benefit was similar across the range of APA/NAPA exposures. In univariate and multivariate Cox regression models, no significant differences in the exposure-MFS relationship were observed for APA and NAPA.
Conclusions
240 mg/d APA provided efficacious drug exposure for the majority of pts, including those who required dose reductions/interruptions due to AEs. The MFS benefit was similar across the range of APA exposure. Dose reductions/interruptions due to AEs did not reduce the efficacy of APA.
Clinical trial identification
NCT01946204.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Editorial Acknowledgement
Writing assistance was provided by Brian Haas, PhD, of PAREXEL, and was funded by Janssen Global Services, LLC.
Disclosure
M.R. Smith: Grants: Janssen; Personal fees: Janssen, Astellas, Bayer. C. Perez-Ruixo, O. Ackaert, D. Ouellet, C. Chien, M.K. Yu, J-J. Perez-Ruixo: Employee: Janssen Research & Development; Stock owner: Johnson & Johnson. H. Uemura: Personal fees: Janssen, Astellas, Takeda, Sanofi, Bayer, Astra-Zeneca. D. Olmos: Grants: Janssen, Astellas, Bayer, Sanofi, Genentech, Astra-Zeneca, Bayer, outside the submitted work. P.N. Mainwaring: Personal fees: XING Technologies P/L, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche; Grants: Merck; Pending patent: XING Technologies P/L: All other authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract